Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.320
-0.020 (-1.49%)
At close: Jan 30, 2026, 4:00 PM EST
1.360
+0.040 (3.03%)
After-hours: Jan 30, 2026, 7:29 PM EST
Heron Therapeutics Employees
Heron Therapeutics had 122 employees as of December 31, 2024. The number of employees decreased by 4 or -3.17% compared to the previous year.
Employees
122
Change (1Y)
-4
Growth (1Y)
-3.17%
Revenue / Employee
$1,271,287
Profits / Employee
-$111,295
Market Cap
242.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 122 | -4 | -3.17% |
| Dec 31, 2023 | 126 | -77 | -37.93% |
| Dec 31, 2022 | 203 | -99 | -32.78% |
| Dec 31, 2021 | 302 | 79 | 35.43% |
| Dec 31, 2020 | 223 | -8 | -3.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 136 |
| Nautilus Biotechnology | 124 |
| Silence Therapeutics | 116 |
| MediWound | 111 |
| Tonix Pharmaceuticals Holding | 81 |
| Armata Pharmaceuticals | 60 |
| Fennec Pharmaceuticals | 32 |
| Achieve Life Sciences | 25 |
HRTX News
- 21 days ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 2 months ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 3 months ago - Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire
- 3 months ago - Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - GlobeNewsWire
- 3 months ago - Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 6 months ago - Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value - PRNewsWire
- 6 months ago - Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha